CD8 + CD4FOXP3 grouping provides an independent prognostic indicator, which can be used to stratify GC patients with a good outcome and possibly responsive to ICB, irrespective of microsatellite instability (MSI) or Epstein–Barr virus (EBV) status. This evidence concerns the gene CD8A and gastric cancer.